Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG

Cees E. van der Poel, Roos A. Karssemeijer, Peter Boross, Joke A. van der Linden, Miranda Blokland, Jan G. J. van de Winkel, Jeanette H. W. Leusen

Blood (2010) 116 (24): 5327–5333.

https://doi.org/10.1182/blood-2010-04-280214

Published: 2010

Includes: Supplemental data

Journal Articles

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

Michael Dechant, MD, Stefan Lohse, PhD, Stefanie Derer, PhD, Thomas Beyer, PhD, Katja Klausz, PhD, Matthias Peipp, PhD, Jeanette H. W. Leusen, PhD, Jan G. J. van de Winkel, PhD, Thomas Valerius, MD

Blood (2010) 116 (21): 1488.

https://doi.org/10.1182/blood.V116.21.1488.1488

Published: 2010

Journal Articles

The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

Pia Glorius, Anne Baerenwaldt, Christian Kellner, Matthias Staudinger, Paul W.H.I. Parren, Jan G. J. van De Winkel, Andreas Humpe, Thomas Valerius, Roland Repp, Falk Nimmerjahn, Martin Gramatzki, Matthias Peipp

Blood (2010) 116 (21): 2846.

https://doi.org/10.1182/blood.V116.21.2846.2846

Published: 2010

Journal Articles

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Yu-Tzu Tai, Ph.D., Michel de Weers, Ph.D., Xian-Feng Li, MS, Weihua Song, MD, Sabikun Nahar, B.S., Joost M Bakker, Tom Vink, Daniëlle Jacobs, Lukas Oomen, Wim K Bleeker, Nikhil C. Munshi, MD, Jan G. J. van de Winkel, PhD, Paul W. H. I. Parren, PhD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 608.

https://doi.org/10.1182/blood.V114.22.608.608

Published: 2009

Journal Articles

Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.

Jenny L Craigen, PhD, Wendy J.M. Mackus, PhD, Patrick Engleberts, Sam R Miller, Sue Speller, Louise C Chamberlain, Bill G Davis, PhD, Simon M McHugh, PhD, Ed Bullmore, PhD, Charles J Cox, PhD, Sally Wetten, Gerrard Perdock, Joost M Bakker, PhD, Jan G. J. van de Winkel, PhD, Paul W. H. I. Parren, PhD

Blood (2009) 114 (22): 1725.

https://doi.org/10.1182/blood.V114.22.1725.1725

Published: 2009

Journal Articles

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Ronald P. Taylor, PhD, Paul V. Beum, PhD, P. Todd Stukenberg, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD, Jan G. J. van de Winkel, PhD

Blood (2008) 112 (11): 1577.

https://doi.org/10.1182/blood.V112.11.1577.1577

Published: 2008

Journal Articles

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Ronald P. Taylor, PhD, Andrew W. Pawluczkowycz, MS, Margaret A. Lindorfer, PhD, Jan G. J. van de Winkel, PhD, Frank J. Beurskens, PhD, Paul W. H. I. Parren, PhD

Blood (2008) 112 (11): 1578.

https://doi.org/10.1182/blood.V112.11.1578.1578

Published: 2008

Journal Articles

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

Frank J. Beurskens, Sigrid R. Ruuls, Patrick J. Engelberts, Tom Vink, Wendy J. Mackus, Jan G. J. van de Winkel, Paul W. H. I. Parren

Blood (2008) 112 (10): 4354–4355.

https://doi.org/10.1182/blood-2008-07-171082

Published: 2008

Journal Articles

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Matthias Peipp, Jeroen J. Lammerts van Bueren, Tanja Schneider-Merck, Wim W. K. Bleeker, Michael Dechant, Thomas Beyer, Roland Repp, Patrick H. C. van Berkel, Tom Vink, Jan G. J. van de Winkel, Paul W. H. I. Parren, Thomas Valerius

Blood (2008) 112 (6): 2390–2399.

https://doi.org/10.1182/blood-2008-03-144600

Published: 2008

Includes: Supplemental data

Journal Articles

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Jessica L. Teeling, Ruth R. French, Mark S. Cragg, Jeroen van den Brakel, Marielle Pluyter, Haichun Huang, Claude Chan, Paul W. H. I. Parren, C. Erik Hack, Michael Dechant, Thomas Valerius, Jan G. J. van de Winkel, Martin J. Glennie

Blood (2004) 104 (6): 1793–1800.

https://doi.org/10.1182/blood-2004-01-0039

Published: 2004

Journal Articles

Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection

Richard J. Pleass, Solabomi A. Ogun, David H. McGuinness, Jan G. J. van de Winkel, Anthony A. Holder, Jenny M. Woof

Blood (2003) 102 (13): 4424–4430.

https://doi.org/10.1182/blood-2003-02-0583

Published: 2003

Journal Articles

Mac-1 (CD11b/CD18) is crucial for effective Fc receptor–mediated immunity to melanoma

Annemiek B. van Spriel, Heidi H. van Ojik, Annie Bakker, Marco J. H. Jansen, Jan G. J. van de Winkel

Blood (2003) 101 (1): 253–258.

https://doi.org/10.1182/blood.V101.1.253

Published: 2003

Journal Articles

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing

Michael Dechant, Gestur Vidarsson, Bernhard Stockmeyer, Roland Repp, Martin J. Glennie, Martin Gramatzki, Jan G. J. van de Winkel, Thomas Valerius

Blood (2002) 100 (13): 4574–4580.

https://doi.org/10.1182/blood-2002-03-0687

Published: 2002

Journal Articles

The cytoplasmic domain of FcγRIIA (CD32) participates in phagolysosome formation

Randall G. Worth, Laura Mayo-Bond, Moo-Kyung Kim, Jan G. J. van de Winkel, Robert F. Todd, III, Howard R. Petty, Alan D. Schreiber

Blood (2001) 98 (12): 3429–3434.

https://doi.org/10.1182/blood.V98.12.3429

Published: 2001

Journal Articles

Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia

Jessica L. Teeling, Theo Jansen-Hendriks, Taco W. Kuijpers, Masja de Haas, Jan G. J. van de Winkel, C. Erik Hack, Wim K. Bleeker

Blood (2001) 98 (4): 1095–1099.

https://doi.org/10.1182/blood.V98.4.1095

Published: 2001

Journal Articles

Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation

Annemiek B. van Spriel, Jeanette H. W. Leusen, Marjolein van Egmond, Henry B. P. M. Dijkman, Karel J. M. Assmann, Tanya N. Mayadas, Jan G. J. van de Winkel

Blood (2001) 97 (8): 2478–2486.

https://doi.org/10.1182/blood.V97.8.2478

Published: 2001

Journal Articles

Presentation of ovalbumin internalized via the immunoglobulin-A Fc receptor is enhanced through Fc receptor γ-chain signaling

Li Shen, Marjolein van Egmond, Karyn Siemasko, Hong Gao, Terri Wade, Mark L. Lang, Marcus Clark, Jan G. J. van de Winkel, William F. Wade

Blood (2001) 97 (1): 205–213.

https://doi.org/10.1182/blood.V97.1.205

Published: 2001

Journal Articles

Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma

Jamie Honeychurch, Alison L. Tutt, Thomas Valerius, Ingmar A. F. M. Heijnen, Jan G. J. Van de Winkel, Martin J. Glennie

Blood (2000) 96 (10): 3544–3552.

https://doi.org/10.1182/blood.V96.10.3544

Published: 2000

NARROW

Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG

Recombinant Dimeric IgA Antibodies as Tumor-Specific Agents.

The Novel Bispecific Antibody [(CD20) 2 xCD16] Efficiently Triggers Lysis of Neoplastic B Cells

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.

Complement (C) Activation Followed by Penetration of the Membrane Attack Complex (MAC) on B Cells Opsonized with CD20 Mabs Allows for Calcium Influx Which Induces Streamers. Generalization of Streaming to Include other Mabs and Target Cells.

Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX.

Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies

Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection

Mac-1 (CD11b/CD18) is crucial for effective Fc receptor–mediated immunity to melanoma

Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing

The cytoplasmic domain of FcγRIIA (CD32) participates in phagolysosome formation

Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia

Mac-1 (CD11b/CD18) is essential for Fc receptor–mediated neutrophil cytotoxicity and immunologic synapse formation

Presentation of ovalbumin internalized via the immunoglobulin-A Fc receptor is enhanced through Fc receptor γ-chain signaling

Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only